Kwality Pharmaceuticals Limited(KPL) is pleased to announce a significant milestone in its pursuit of expanding its biologics portfolio. The company has secured approval from the Review Committee on Genetic Manipulation (RCGM) to advance pre-clinical toxicity studies for its recombinant Erythropoietin product, formulated at a concentration of 10,000 IU/mL.

Erythropoietin, a critical therapeutic agent, is widely used in the treatment of anemia associated with chronic kidney disease (CKD). This approval represents a pivotal step in Kwality Pharmaceuticals' commitment to addressing some of the most pressing healthcare challenges globally. The company is now well-positioned to complete pre-clinical studies and is meticulously preparing for the eventual commercialization of this promising biologic within the next fiscal year.

In addition to its work in the biologics sector, Kwality Pharmaceuticals continues to excel in the production, distribution, and sale of a wide range of pharmaceutical goods, including drug intermediates, chemicals, extracts, alkaloids, medicines, and medical preparations, alongside beverages and toilet requisites.

Ramesh Arora, Managing Director of Kwality Pharmaceuticals, expressed enthusiasm regarding this development, highlighting the company’s unwavering dedication to advancing healthcare solutions through innovation. He reaffirmed the company’s focus on enhancing global health outcomes with its expanding biologics offerings.
This milestone underscores Kwality Pharmaceuticals' strengthening position in the biologics sector and further affirms its role as a key player in delivering innovative, life-changing therapies to meet critical healthcare needs worldwide.